GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

Pacific Shuanglin Bio-pharmacy Co 000403.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

9.40

-3.29%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Pacific Shuanglin Bio-pharmacy Co

Its shares trade on Shenzhen under the ticker 000403.SZ. It has been listed since 28 June 1996. In the fiscal year to 31 December 2025, it reported revenue of CN¥2.63bn and net income of CN¥419.3m. At that date it held total assets of CN¥9.47bn and shareholders' equity of CN¥8.09bn.

Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the production and marketing of pharmaceutical products. The company is headquartered in Zhanjiang, Guangdong. The firm's main products are human albumin, intravenous immunoglobulin (pH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin. The firm mainly operates its business in the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
28 Jun 1996
Employees
2,093
Website
plbio.cn ↗

Leadership

Pay as last reported

  • Mr. Hao LiChairman of the Board, since 2023
  • Ms. Shaolan FuCo-Chairman of the Board, since 2023
  • Ms. Yehong WangChief Financial Officer
  • Mr. Xiankui RongGeneral Manager
  • Ms. Xiaoying HuangDeputy General Manager, Director, since 2023
  • Mr. Lei YanDeputy General Manager, Director, since 2023
  • Ms. Lan YeDeputy General Manager, Director, since 2023
  • Jianmin YuanExecutive Deputy General Manager, Director, since 2005CN¥826,400
  • Mr. Zhibo WangDeputy General Manager
  • Hong YanDeputy General ManagerCN¥108,200
  • Mr. Bin YangDeputy General Manager
  • Mr. Qunge ZhangDeputy General Manager

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Human albumin and intravenous immunoglobulin are key products in the domestic market.
  • Zhanjiang, Guangdong headquarters supports local market operations.
  • 2093 employees ensure stable production capacity and service.

Weaknesses

  • Domestic market focus limits international expansion opportunities.
  • Limited product range compared to global biotechnology firms.
  • No mention of R&D investment in the provided facts.

Opportunities

  • Growing demand for immunoglobulin products in China's healthcare sector.
  • Expansion into international markets for human albumin sales.
  • Increased healthcare spending in Guangdong province.

Threats

  • Competition from international biotechnology companies in China.
  • Regulatory changes affecting pharmaceutical production in CN.
  • Economic downturn impacting healthcare sector spending.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.